Alpha 2.0
Login Register
» Authors » Tsuguru Hayashi

Tsuguru Hayashi

Explore the profile of Tsuguru Hayashi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 22
Citations 190
Followers 0
Related Specialties
General Medicine
Science
Gastroenterology
Top 10 Co-Authors
Masaru Harada
Shinji Oe
Yuichi Honma
Koichiro Miyagawa
Yutaka Yasui
Kenta Takaura
Michihiko Shibata
Masayuki Kurosaki
Namiki Izumi
Jun Itakura
Published In
PLoS One
Intern Med
Hepatol Res
Exp Cell Res
Sci Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
Excess glucose alone induces hepatocyte damage due to oxidative stress and endoplasmic reticulum stress
Hayashi T, Oe S, Miyagawa K, Kusanaga M, Ogino N, Honma Y, et al.
Exp Cell Res . 2024 Sep; 442(2):114264. PMID: 39313175
Type 2 diabetes mellitus (DM) is a significant risk factor for metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatocellular carcinoma (HCC). With the increasing prevalence of type 2 DM and...
2.
Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study
Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, et al.
Hepatol Res . 2024 Jul; 54(12):1215-1225. PMID: 38990762
Aim: Recent genome-wide association studies of European populations have identified rs16906115, a single-nucleotide polymorphism in the interleukin-7 gene, as a predictor of immune-related adverse events (irAEs) and the therapeutic efficacy...
3.
Child-Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma
Yoshitomi K, Hayashi T, Oe S, Shibata M, Honma Y, Harada M, et al.
Sci Rep . 2024 Feb; 14(1):3707. PMID: 38355630
Transcatheter arterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC). However, TACE can cause deterioration of liver functions. We aimed to identify the factors that influence deterioration...
4.
Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C
Honma Y, Shibata M, Morino K, Koya Y, Hayashi T, Ogino N, et al.
Dig Dis Sci . 2022 Sep; 68(2):685-698. PMID: 36100828
Background: The incidence of extrahepatic malignancies (EHMs) after hepatitis C virus (HCV) eradication by interferon (IFN)-based and IFN-free direct-acting antivirals (DAAs) treatment remains unclear. Aims: The aim was to evaluate...
5.
Endoscopic injection sclerotherapy improves liver function compared with endoscopic variceal ligation
Hayashi T, Watanabe T, Shibata M, Kumei S, Oe S, Miyagawa K, et al.
Sci Rep . 2021 Oct; 11(1):20479. PMID: 34650156
Liver function is a most important prognostic factor in patients with liver cirrhosis. Also, portal hypertension is a fatal complication of liver cirrhosis and variceal treatment is indispensable. However, changes...
6.
Rapid Progression of Liver Fibrosis Induced by Acute Liver Injury Due to Immune-related Adverse Events of Atezolizumab
Honma Y, Shibata M, Gohda T, Matsumiya H, Kumamoto K, Miyama A, et al.
Intern Med . 2021 Jan; 60(12):1847-1853. PMID: 33456046
A 72-year-old woman with advanced lung cancer had received systemic chemotherapy including atezolizumab. About three months after the initial administration of atezolizumab, her liver enzyme levels increased. The histopathological findings...
7.
Correlation of hepatitis C virus-mediated endoplasmic reticulum stress with autophagic flux impairment and hepatocarcinogenesis
Honma Y, Miyagawa K, Hara Y, Hayashi T, Kusanaga M, Ogino N, et al.
Med Mol Morphol . 2021 Jan; 54(2):108-121. PMID: 33386512
Hepatitis C virus (HCV) infection has been known to use autophagy for its replication. However, the mechanisms by which HCV modulates autophagy remain controversial. We used HCV-Japanese fulminant hepatitis-1-infected Huh7...
8.
C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib
Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M
PLoS One . 2020 Dec; 15(12):e0244370. PMID: 33351844
Background And Aim: Lenvatinib has become a first line treatment for unresectable hepatocellular carcinoma (HCC). However, continued administration is impossible in many patients due to treatment resistance and severe adverse...
9.
Antiplatelet Therapy Improves the Prognosis of Patients with Hepatocellular Carcinoma
Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M
Cancers (Basel) . 2020 Nov; 12(11). PMID: 33142758
Aims: Antiplatelet therapy has been reported to reduce liver fibrosis and hepatocellular carcinoma (HCC), and has exhibited antitumor properties in other cancers. However, the effects of antiplatelet therapy after diagnosis...
10.
Use of the Serum Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients
Hayashi T, Tamaki N, Kurosaki M, Wang W, Okada M, Higuchi M, et al.
Diagnostics (Basel) . 2020 Apr; 10(3). PMID: 32235806
Background: A test to narrow down patients who require esophagogastroduodenoscopy (EGD) with a high probability of having gastroesophageal varices (GEV) and a high-risk of liver-related events is an unmet need....